^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

RNF43 mutation

i
Other names: RNF43, Ring Finger Protein 43, RING-Type E3 Ubiquitin Transferase RNF43, E3 Ubiquitin-Protein Ligase RNF43, RING Finger Protein 43, EC 2.3.2.27, RNF124
Entrez ID:
Related biomarkers:
Phase 1/2
Children's Oncology Group
Recruiting
Last update posted :
04/22/2024
Initiation :
11/08/2021
Primary completion :
06/30/2028
Completion :
06/30/2028
RNF43 • CTNNB1 • TCF7L2
|
APC mutation • CTNNB1 mutation • RNF43 mutation • CTNNB1 S45P
|
tegavivint (BC2059)
Phase 1
Novartis Pharmaceuticals
Active, not recruiting
Last update posted :
03/15/2024
Initiation :
12/01/2011
Primary completion :
06/14/2021
Completion :
06/18/2024
BRAF • RNF43
|
BRAF mutation • RNF43 mutation
|
spartalizumab (PDR001) • WNT974
Phase 2
Redx Pharma Plc
Completed
Last update posted :
03/08/2024
Initiation :
12/10/2021
Primary completion :
11/30/2023
Completion :
11/30/2023
RNF43
|
RNF43 mutation
|
Keytruda (pembrolizumab) • Prolia (denosumab) • zamaporvint (RXC004)
Phase 1
Eisai Co., Ltd.
Active, not recruiting
Last update posted :
03/06/2024
Initiation :
03/05/2019
Primary completion :
03/31/2025
Completion :
03/31/2025
RNF43 • APC • AXIN1 • ZNRF3
|
APC mutation • CTNNB1 mutation • RNF43 mutation
|
E7386
Phase N/A
Zhejiang Cancer Hospital
Recruiting
Last update posted :
08/15/2023
Initiation :
12/01/2021
Primary completion :
12/31/2025
Completion :
12/31/2025
EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • HRAS • CDKN2A • AKT1 • TOP2A • IL6 • RNF43 • CTNNB1 • FBXW7 • MUC16 • GNAS • PPP2R1A
|
KRAS mutation • BRAF mutation • FGFR2 mutation • RNF43 mutation • AKT1 mutation
Phase N/A
Medical University of Vienna
Completed
Last update posted :
09/06/2022
Initiation :
05/01/2014
Primary completion :
12/31/2021
Completion :
12/31/2021
EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A
|
PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation
Phase 1b
Curegenix Inc.
Recruiting
Last update posted :
01/26/2022
Initiation :
02/01/2016
Primary completion :
03/01/2023
Completion :
03/01/2023
BRAF • RNF43 • CTNNB1 • AXIN1 • RSPO2 • RSPO3
|
BRAF V600E • BRAF V600 • RNF43 mutation • RSPO3 fusion
|
Keytruda (pembrolizumab) • Erbitux (cetuximab) • Braftovi (encorafenib) • CGX1321
Phase N/A
Medical University of Vienna
Completed
Last update posted :
02/25/2020
Initiation :
02/01/2012
Primary completion :
11/01/2018
Completion :
11/01/2018
EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A
|
PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation
Phase 1/2
Array BioPharma
Completed
Last update posted :
10/09/2017
Initiation :
12/01/2014
Primary completion :
05/31/2016
Completion :
06/23/2017
KRAS • RNF43
|
KRAS mutation • BRAF V600 • KRAS wild-type • RAS wild-type • RNF43 mutation
|
Erbitux (cetuximab) • Braftovi (encorafenib) • WNT974